Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AGfiledCriticalBayer Pharma AG
Priority claimed from PCT/EP2014/053573external-prioritypatent/WO2014131739A2/en
Publication of MA38364A1publicationCriticalpatent/MA38364A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
La présente invention concerne des composés imidazopyridazines substitués, des procédés de préparation desdits composés, des compositions pharmaceutiques et des combinaisons comprenant lesdits composés et l'utilisation desdits composés pour la fabrication d'une composition pharmaceutique pour le traitement ou la prophylaxie d'une maladie, en particulier un trouble hyper-prolifératif et/ou un trouble de l'angiogenèse, en tant qu'agent unique ou en combinaison avec d'autres principes actifs.The present invention relates to substituted imidazopyridazine compounds, processes for the preparation of said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular a hyper-proliferative disorder and / or a disorder of angiogenesis, as a single agent or in combination with other active ingredients.
AMINOALCOOL-SUBSTITUTED 2,3-DIHYDROIMIDAZO [1,2-C] QUINAZOLEIN DERIVATIVES USEFUL IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS AND ANGIOGENESIS RELATED DISEASES